Top View
- New Drug Updates in Solid Tumors: PARP Inhibitors in Ovarian Cancer, Immunotherapeutics, and Other Agents
- The Potent ALK Inhibitor Brigatinib (AP26113)
- Targeted Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer
- Dosing Guide
- Safety and Efficacy of Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors in Non‑Small Cell Lung Cancer (Review)
- Brigatinib, a New Treatment Option in ALK-Rearranged Advanced Non-Small Cell Lung Carcinoma
- Overview of Current Type I/II Kinase Inhibitors
- Combined Cellular and Biochemical Profiling to Identify Predictive Drug Response Biomarkers for Kinase Inhibitors Approved for Clinical Use Between 2013 and 2017
- Chemotherapy Protocol Lung Cancer Brigatinib Regimen • NSCLC
- Product Monograph
- T.; Siedentopf, O.; Birkle, M.; Pathe, M; Ehlert, JE, and Kubbutat, M
- Rozlytrek, INN-Entrectinib)
- Brigatinib Versus Other Second-Generation ALK Inhibitors
- Proton Pump Inhibitors and Oncologic Treatment Efficacy
- Repurposing Tyrosine Kinase Inhibitors to Overcome Multidrug Resistance in Cancer: a Focus on Transporters and Lysosomal Sequestration
- List of Cleared Or Approved Companion Diagnostic Devices (In Vitro and Imaging Tools)
- Identification of Existing Drugs That Effectively Target NTRK1 and ROS1 Rearrangements in Lung Cancer
- Items Supported by the CCF Medical Assistance Programmes
- Brigatinib in Anaplastic Lymphoma Kinase-Rearranged Non-Small Cell Lung Cancer
- Molecular Diagnostics
- Therapeutic Sequencing in ALK+ NSCLC
- Drug Combo Beats Vemurafenib Alone for Colorectal Cancer
- Emetic Risk of Single Intravenous Antineoplastic Agents in Adults
- Policy Drug(S) Type of Change Brief Description of Policy Change UM ONC 1035 5HT3 Receptor Formatting N/A
- Combined Cellular and Biochemical Profiling to Identify Predictive Drug Response Biomarkers for Kinase Inhibitors Approved for Clinical Use Between 2013 and 2017
- Anaplastic Lymphoma Kinase Inhibitors for Advanced Non-Small Cell Lung Carcinoma
- Drug-Related Pneumonitis in Cancer Treatment During the COVID-19 Era
- Brigatinib: New-Generation ALK Inhibitor for Nonsmall Cell Lung Cancer
- ALUNBRIG® (Brigatinib) Tablets, for Oral Use Initial U.S
- Modeling Clinical Responses to Targeted Therapies by Patient-Derived Organoids of Advanced Lung Adenocarcinoma
- New Therapeutic Approaches to Overcoming Resistant EGFR Exon 20 Alterations
- Current Insights Into Combination Therapies with MAPK Inhibitors and Immune Checkpoint Blockade
- LCRF 2020 Reckamp 111720-Logo
- ALUNBRIG and Obtain Ophthalmologic Evaluation, Then Dose Reduce Or ALUNBRIG Safely and Effectively